COMBINED MODALITY TREATMENT WITH INTENSIFIED CHEMOTHERAPY AND DOSE-REDUCED INVOLVED FIELD RADIOTHERAPY IN PATIENTS WITH EARLY UNFAVOURABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD11 TRIAL

被引：0
|
作者：
Engert, A.
Borchmann, P.
Diehl, V. [1 ]
Goergen, H. [1 ]
Mueller, H. [1 ]
Mueller, R.
Eich, H.
Mueller-Hermelink, H. [2 ]
Herrmann, R. [3 ]
Markova, J. [4 ]
Ho, A. [5 ]
Hiddemann, W. [6 ]
Doerken, B. [7 ]
Greil, R. [8 ]
机构：
[1] Univ Hosp Cologne, CHSG, Cologne, Germany
[2] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[3] Kantonsspital Basel, Basel, Switzerland
[4] Univ Hosp Prague, Prague, Czech Republic
[5] Heidelberg Univ, Med Clin V, Heidelberg, Germany
[6] Univ Hosp Grosshadern, Munich, Germany
[7] Charite, D-13353 Berlin, Germany
[8] Salzburg Univ, A-5020 Salzburg, Austria
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0410
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [21] Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
    von Tresckow, Bastian
    Pluetschow, Annette
    Fuchs, Michael
    Klimm, Beate
    Markova, Jana
    Lohri, Andreas
    Kral, Zdenek
    Greil, Richard
    Topp, Max S.
    Meissner, Julia
    Zijlstra, Josee M.
    Soekler, Martin
    Stein, Harald
    Eich, Hans T.
    Mueller, Rolf P.
    Diehl, Volker
    Borchmann, Peter
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (09) : 907 - 913
  • [22] Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10.
    Engert, Andreas
    Diehl, Volker
    Pluetschow, Annette
    Eich, Hans T.
    Herrmann, Richard
    Doerken, Bernd
    Kanz, Lothar
    Greil, Richard
    Markova, Jana
    Fuchs, Michael
    Borchmann, Peter
    Mueller-Hermelink, Hans Konrad
    Mueller, Rolf Peter
    BLOOD, 2009, 114 (22) : 299 - 299
  • [23] Two cycles of ABVD followed by involved field radiotherapy with 20 Gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10 study
    Engert, A.
    Diehl, V
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermeling, H. K.
    Mueller, R. P.
    ONKOLOGIE, 2010, 33 : 124 - 124
  • [24] TWO CYCLES OF ABVD FOLLOWED BY INVOLVED FIELD RADIOTHERAPY WITH 20 GRAY (GY) IS THE NEW STANDARD OF CARE IN THE TREATMENT OF PATIENTS WITH EARLY-STAGE HODGKIN LYMPHOMA: FINAL ANALYSIS OF THE RANDOMIZED GERMAN HODGKIN STUDY GROUP (GHSG) HD10 STUDY
    Engert, A.
    Pluetschow, A.
    Eich, H.
    Herrmann, R.
    Doerken, B.
    Kanz, L.
    Greil, R.
    Markova, J.
    Fuchs, M.
    Borchmann, P.
    Mueller-Hermelink, H.
    Mueller, R.
    Diehl, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 473 - 473
  • [25] Mortality during treatment of patients with advanced Hodgkin's lymphoma undergoing dose escalated BEACOPP chemotherapy: An analysis of the German Hodgkin study group (GHSG).
    Fuchs, M
    Franklin, J
    Klimm, B
    Josting, A
    Pfistner, B
    Engert, A
    Diehl, V
    BLOOD, 2005, 106 (11) : 749A - 749A
  • [26] BEACOPP chemotherapy in elderly patients with advanced Hodgkin's disease: Analysis of the randomized trial HD9 for elderly patients of the German Hodgkin lymphoma study group (GHSG).
    Ballova, V
    Franklin, J
    Josting, A
    Wolf, J
    Diehl, V
    Engert, A
    BLOOD, 2003, 102 (11) : 400A - 400A
  • [27] ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials
    Boell, Boris
    Goergen, Helen
    Fuchs, Michael
    Pluetschow, Annette
    Eich, Hans Theodor
    Bargetzi, Mario J.
    Weidmann, Eckhart
    Junghanss, Christian
    Greil, Richard
    Scherpe, Alexander
    Schmalz, Oliver
    Eichenauer, Dennis A.
    von Tresckow, Bastian
    Rothe, Achim
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (12) : 1522 - 1529
  • [28] Is an additive Radiotherapy for Patients in advanced Stages of a necessary Hodgkin's Lymphoma? - Final analysis of the HD12 trial of the German Hodgkin Study Group
    Kriz, J.
    Borchmann, P.
    Haverkamp, H.
    Diehl, V
    Mueller, R. -P
    Engert, A.
    Eich, H. -T
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 30 - 30
  • [29] Reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: Interim analysis of the HD 10 trial of the GHSG.
    Diehl, V
    Brillant, C
    Engert, A
    Wolf, J
    Nogova, L
    Mueller, RP
    Eich, H
    Mueller-Hermelink, HK
    Herrmann, R
    Doerken, B
    Kanz, L
    Greil, R
    Pfistner, B
    BLOOD, 2004, 104 (11) : 368A - 368A
  • [30] Biophysical analysis of acute toxicity of radiotherapy in Hodgkin's lymphoma - A comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group (GHSG)
    Eich, H
    Haverkamp, U
    Engert, A
    Kocher, M
    Skripnitchenko, R
    Sehlen, S
    Duehmke, E
    Diehl, V
    Mueller, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S219 - S219
12345